Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-PRISM: Elotuzumab combination in high-risk smoldering multiple myeloma
NCT02279394Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2014
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in smoldering multiple myeloma (SMM), sponsored by Dana-Farber Cancer Institute. Started Dec 2014; status: completed.
02
Drugs
elotuzumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02279394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279394.